Conditions: Healthy Volunteers
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 26
Healthy volunteers: yes

Brief summary:
The main purpose of this study is to determine how much evacetrapib gets into the blood stream and how long it takes the body to get rid of it when given with rifampin. The safety and tolerability of the two drugs, given together, will also be evaluated. The study will also look at blood cholesterol levels and levels of a hormone called cortisol before and after taking rifampin. Information about any side effects that may occur will also be collected.

For each participant, this study will include 2 periods in fixed order. The study will last approximately 29 days.

Detailed description:

Arms:
arm 1: Period 1:

130 milligram (mg) evacetrapib administered orally, once on Day 1 arm 2: Period 2:

Rifampin: 600 mg administered orally, once daily (QD) for 14 days (Days 9 to 22)

Evacetrapib: 130 mg administered orally once on Day 16

Interventions: intervention 1: Evacetrapib intervention 2: Rifampin
Intervention descriptions: intervention 1: Administered orally intervention 2: Administered orally

Protocol document: